Robby Newman

Robby Newman, Ph.D. has extensive experience in the field of immunology and cancer biology. Currently serving as a Principal Scientist at Mural Oncology, Robby is a major contributor to biologics target ideation and leads pre-clinical immuno-oncology pipeline projects. Prior to this role, Robby held various positions at Alkermes and Altor Bioscience Corporation where Robby demonstrated expertise in pharmacology, biology, and leading research projects. With a Ph.D. from the University of Miami Miller School of Medicine, Robby's career has been marked by significant contributions to the field of oncology research and innovative scientific collaborations.